Shattuck Labs (NASDAQ:STTK – Get Free Report) had its target price raised by research analysts at Needham & Company LLC from $17.00 to $19.00 in a research note issued on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s price target indicates a potential upside of 177.78% from the company’s current price.
A number of other brokerages have also recently commented on STTK. JPMorgan Chase & Co. began coverage on Shattuck Labs in a research report on Friday, July 24th. They issued an “overweight” rating and a $10.00 price target on the stock. TD Cowen upgraded shares of Shattuck Labs to a “strong-buy” rating in a research note on Monday, August 24th. Jefferies Financial Group raised shares of Shattuck Labs to an “outperform” rating and set a $7.00 target price on the stock in a report on Friday, June 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Shattuck Labs in a research report on Friday, September 11th. Finally, Wall Street Zen downgraded shares of Shattuck Labs from a “buy” rating to a “hold” rating in a report on Saturday, August 15th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $13.00.
Check Out Our Latest Stock Report on STTK
Shattuck Labs Stock Up 0.3%
Shattuck Labs (NASDAQ:STTK – Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.12) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.12). On average, research analysts expect that Shattuck Labs will post -0.45 EPS for the current year.
Institutional Trading of Shattuck Labs
Large investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in shares of Shattuck Labs in the 2nd quarter valued at approximately $27,315,000. Frazier Life Sciences Management L.P. bought a new stake in shares of Shattuck Labs during the 2nd quarter valued at approximately $26,025,000. NEXTBio Capital Management LP acquired a new position in Shattuck Labs during the 4th quarter worth approximately $11,497,000. Wellington Management Group LLP bought a new position in Shattuck Labs in the 2nd quarter valued at approximately $12,269,000. Finally, S&G Foundation bought a new position in Shattuck Labs in the 2nd quarter valued at approximately $3,024,000. 58.74% of the stock is owned by institutional investors and hedge funds.
About Shattuck Labs
Shattuck Labs, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s research is based on its Agonist Redirected Checkpoint (ARC) platform, which is designed to create bifunctional fusion proteins that combine immune-cell activation with the targeted blocking of immune-suppressive pathways.
Shattuck’s lead investigational programs are intended to stimulate antitumor immune responses within the tumor microenvironment.
Featured Articles
- Five stocks we like better than Shattuck Labs
- Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
- Alamos Gold’s 1 Million-Ounce Growth Story Is Hiding in Plain Sight
- Everyone in AI Is Quietly Copying Palantir’s Playbook
- Advanced Micro Devices Is Spending $8.2 Billion to Learn What AI Needs Next
Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with MarketBeat.com's FREE daily email newsletter.
